Orphan Drugs Plus REMS: A Perfect Fit?
This article was originally published in RPM Report
Executive Summary
Biopharma companies have a decidedly mixed view of FDA's new post-marketing safety authorities. But for one industry segment-companies concentrating in serving very small patient populations suffering from rare diseases-the new regulatory model is decidedly good for business. What does that mean for the future of Big Pharma?
You may also be interested in...
Orphan Drug Standards: Systematic Flexibility
The National Organization for Rare Disorders wants FDA to be a bit more rigorous in communicating its regulatory standards. The agency has always been flexible in determining how much evidence of safety and efficacy is necessary when it comes to orphan drugs; sponsors, investors and patients would benefit if that is more clearly spelled out.
Investing in Unpredictable Times: A Conversation with Biotech-CEO-Turned-VC David Mott
Former MedImmune CEO David Mott discusses the key regulatory and reimbursement risks in drug development. While he sees plenty of venture capitalist money for truly innovative products, there are several areas he tends to avoid at all costs: vaccines, antibiotics, diabetes and-over the longer term-oncology drug development.
Doing Well By Doing Good: FDA's Orphan Product Head Makes His Case to Pharma
Tim Coté has been a tireless advocate for greater involvement by Big Pharma in orphan drug research since taking over as head of FDA's Orphan Products Office two years ago. We talked to him about the response he's heard so far.